Kornimate/medical-research-clean huggingface dataset:
community health workers united to reduce colorectal cancer and cardiovascular disease among people at higher risk

Conditions: Colorectal Cancer

Summary: the overall goal of this study is to develop a comprehensive, culturally tailored community-based colorectal cancer (crc) prevention model with a dual emphasis on reducing crc risk along with its cvd risk factors. the study intervention has two components: screening, brief intervention, and referral to treatment (sbirt) to address crc screening and a web-based lifestyle program called "alive!" to address cvd risk factors linked to crc. the c.h.u.r.c.h. trial (community health workers (chw) united to reduce colorectal cancer and cardiovascular disease among people at higher risk) has four specific aims: (1) to compare the effect of a chw-led sbirt (intervention) to referral as usual (rau) (usual care) on guideline-concordant crc screening uptake; (2) to evaluate the effect of a culturally adapted chw-linked alive! (caca) program incorporated into the intervention arm on dietary inflammatory score (dis); (3) to evaluate the effect of caca on changes in life simple-7 (ls7) scores; and (4) to examine the multi-level contextual mechanisms and factors influencing chw effectiveness, reach, and implementation of crc screening uptake and caca activities through a mixed-methods process evaluation. given the broad reach and influence of black churches, results from this study can be used to inform future scale up of this multi-pronged intervention.

colorectal cancer (crc) is the second most lethal cancer in the u.s with the highest incidence and mortality rates among african americans (aas) compared to other racial groups. despite these disparities, which includes premature mortality, aas are the least likely to undergo crc screening, have precancerous colorectal polys removed, and have crc detected at stages early enough for curative excision. lower screening rates are linked to the downstream effects of structural inequities such as access to care, knowledge of screening options and benefits, health system mistrust, fear and anxiety. although reducing the burden of crc is best accomplished by screening, compelling evidence links inflammatory diets and cardiovascular disease (cvd) risk factors to increased crc risk. this proposal aims to develop a community-based prevention model to reduce crc and cardiovascular disease (cvd) risk among aas.

Eligibility criteria:
inclusion criteria: 1. english-speaking 2. self-identifying as black 3. aged 45 years and older 4. not up-to-date with crc 5. working telephone 6. can provide informed consent exclusion criteria: 1. non-english speaking 2. \<45 years old

Keywords: community health workers colorectal cancer cardiovascular disease screening prevention
herombopag olamine in the treatment of thrombocytopenia after chemotherapy

Conditions: Malignant Tumors of the Digestive System; Trombocitopenia

Summary: to evaluate the efficacy and safety of hetrombopag in the treatment of thrombocytopenia after chemotherapy in patients with digestive system malignant tumors


Eligibility criteria:
inclusion criteria: 1. volunteer to participate in clinical research and sign informed consent; 2. age ≥18 years; 3. digestive system malignancy confirmed by histology or cytology; having used oxaliplatin combined with fluorouracil for at least one cycle of 21-day chemotherapy regimen (capox or sox regimen), platelet index after chemotherapy: ≥25×109/l and ≤75×109/l; 4. at least 10 days between tpo, il-11 or platelet transfusion; 5. ecog 0 to 2 points; 6. expected survival time \> 3 months; 7. sufficient organ function for subsequent chemotherapy; 8. women of reproductive age must be willing to use adequate contraception during the study of drug treatment. exclusion criteria: 1. thrombocytopenia caused by non-tumor chemotherapy drugs occurred within 6 months before screening, including but not limited to edta-dependent pseudothrombocytopenia, hypersplenism, infection, and bleeding; 2. have any hematological malignancies, including leukemia, myeloma, bone marrow proliferative diseases, lymphoma or bone marrow proliferative diseases; 3. clinically significant acute or active bleeding within the week prior to screening; 4. subject has medically known hereditary prethrombotic syndrome (e.g., factor v leiden mutation, prothrombin g20210a mutation, or hereditary antithrombin iii (atiii) deficiency) 5. the subject has a history of major cardiovascular disease (e.g., congestive heart failure (new york heart association class 3/ cardiac function), known arrhythmias (e.g., atrial fibrillation) that increase the risk of thromboembolic events, coronary stenting, angioplasty, or coronary artery bypass grafting); 6. subjects had a history of arterial or venous thrombosis within 3 months before screening; 7. use of a vitamin k antagonist (including low molecular weight heparin, factor xa inhibitor, or thrombin inhibitor) within 7 days prior to screening; 8. the subject has a history of chronic platelet or hemorrhagic disorders, or thrombocytopenia from causes other than cit (e.g., chronic liver disease or immune thrombocytopenic purpura); 9. tpo, il-11 or platelet infusion were used within 10 days before enrollment; 10. previous use of thrombopoietin receptor agonists (e.g., eltrobopag, romiestine, etc.) 11. those who cannot be treated with oral drugs; 12. allergic to hetrombopag or any excipient; 13. those whose organ function could not tolerate further antitumor therapy as assessed by the investigator; this product is not recommended for use or discontinuation of treatment in patients who meet any of the following criteria for liver function alt and ast \> 8 x uln. alt or ast\>5×uln for 2 weeks; alt or ast\>3xuln (total bilirubin \>2xuln or inr\>1.5); alt or ast\>3×uln with progressive fatigue, nausea, vomiting, right upper abdominal pain or tenderness, fever, rash, and/or eosinophilia (\>5%).
bilateral and unilateral horizontal strabismus surgery

Conditions: Strabismus

Summary: this study was done in alternating strabismus patients to compare symmetrical muscle surgery and asymmetrical one as regard efficacy and lateral incomitance after surgery


Eligibility criteria:
inclusion criteria: * more than 3 years old. * alternating esotropia or exotropia exclusion criteria: * unilateral strabismus * paralytic or restrictive strabismus
post covid-19 quality of life after hospital discharge in patients treated with niv/c-pap

Conditions: Quality of Life

Summary: a multicenter longitudinal study with data collection at 4 and 8 months after hospital discharge.

the study population consisted of patients treated with niv/cpap, admitted to the covid-19 wards of the ao ss antonio e biagio and cesare arrigo in alessandria (the promoting center), the azienda sanitaria locale bt (barletta, andria, trani) and the azienda socio sanitaria territoriale in lecco, from november 2020 to june 2021. the study assessed at 4 and 8 months after hospital discharge in the patient's home environment, quality of life, residual disability, anxiety and insomnia. enrollment took place only after the approval of the ethics committee of each participating center.

Eligibility criteria:
inclusion criteria: all patients aged ≥18 years admitted for covid-19 pneumonia treated with niv/cpap, discharged to their home with a negative molecular swab and signed informed consent were included in the study exclusion criteria: exclusion criteria were set in; patients admitted for covid-19 pneumonia treated with niv/cpap and invasive ventilation and patients with pre-existing cognitive disorders at the hospital admission date.
comparisons of intravenous ceftriaxone with intravenous moxifloxacin in ercp

Conditions: Cholangitis

Summary: background and aims: the use of prophylactic antibiotics before endoscopic retrograde cholangiopancreatography (ercp) is recommended by all major international gastroenterological societies, especially in the presence of an obstructed biliary system. their use is intended to decrease or eliminate the incidence of complications following the procedure, namely cholangitis, cholecystitis, septicemia, and pancreatitis. however, there were a few reports concerning the dosage, duration and adopting antibiotics most suitable for this purpose. the aim of this prospective comparative study is to compare the occurrence rate of post-procedural complications, such as cholangitis, bacteremia and septicemia between intravenous moxifloxacin and ceftriaxone for the prophylactic use in patients with bile duct obstruction who will undergo therapeutic ercp procedure. methods: in this prospective study, a total of 160 patients (calculated by ibm spss sample power, version 3.0) with bile duct obstruction due to variable causes (bile duct stones, benign or malignant stricture, etc) will be enrolled and randomly allocated to intravenous moxifloxacin and ceftriaxone group, respectively (using simple randomization program). intravenous moxifloxacin (400 mg/day, infused more than 60 min) or ceftriaxone (2 g/day, diluted in 40 cc of 5% dextrose water, infused more than 30 min) will be given 90 minutes before ercp procedure, and will be given to a patient for more than 3 days if the patient develops symptoms and signs of cholangitis or septicemia.


Eligibility criteria:
inclusion criteria: * patients with bile duct obstruction due to variable causes (bile duct stones, benign or malignant stricture, etc) exclusion criteria: * pregnancy * hypersensitivity to moxifloxacin and/or ceftriaxone * previous antibiotic exposure or theophyllin derivatives medication within 14 days of admission * previous history of epilepsy * previous history of endocarditis of valvular heart disease

Keywords: bile duct obstruction cholangitis moxifloxacin ceftriaxone sepsis
comparison the safety and pharmacokinetic characteristics of dwp422 25 mg with those of enbrel 25mg pfs inj. after subcutaneous injection in healthy male volunteers

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study was to compare the safety and pharmacokinetic characteristics of dwp422 25 mg with those of enbrel 25mg pfs inj. after subcutaneous injection in healthy male volunteers.


Eligibility criteria:
inclusion criteria: 1. healthy males, 20 to 45 years of age the moment of screening 2. body mass index is between 19.0 and 27.0 kg/m2 exclusion criteria: 1. hypersensitivity response to the experimental and comparator drugs 2. the tuberculosis patient or latent tuberculosis patient
caries sealing using giomer and glass ionomer cement with or without silver diamine fluoride

Conditions: Caries, Dental; Caries Class I

Summary: the purpose of this study is to evaluate and compare the clinical performance of giomer and gic restorations with and without sdf on caries sealing of primary molar teeth

restorations will be placed on four primary molar teeth with occlusal caries, in a split mouth design. 100 patients will be included in the study. the teeth will be randomized into four groups according to the restorative materials. group 1: sdf (riva star) + giomer (beautifil ii, (shofu dental, tokyo, japan) group 2: giomer (beautifil ii, (shofu dental, tokyo, japan) group 3: sdf (riva star) + gic (equia forte, gc, japan) group 4: gic (equia forte, gc, japan) the restorations will be evaluated clinically at baseline and 6., 12., 18., 24. months and radiologically at 6., 12. and 24. months. the modified us public health service criteria (secondary caries, marginal integrity, marginal discoloration and retention) will be used for clinical evaluation of restorations. intra-oral photos will be taken directly after treatment and at control appointments. the data will be analysed statistically using wilcoxon test, chi square test and the kaplan-meier survival method will be used to estimate survival percentages.

Eligibility criteria:
inclusion criteria: * patients and parents of the patients who accept to participate and sign the informed consent. * patients who have at least four first and/or second primary molars that require class i restorations * teeth that have healthy lamina dura and periodontal ligament * teeth that have caries lesions not extending to the pulp radiographically * patients whose first molar teeth are in occlusion exclusion criteria: * patients and parents of the patients who does not accept to participate and sign the informed consent * teeth which need endodontic treatment * teeth that have caries more than one surface * teeth that are previously restored * patients who are not cooperative for the dental procedure * teeth that doesn't have proximal or occlusal contacts with adjacent healthy teeth * patients who have bruxism, skeletal or dental malocclusion * teeth that have developmental defects/anomalies or discoloration * patients who have allergies to resin based restorative materials

Keywords: primary teeth silver diamine fluoride caries sealing
comparison of laparoscopic pylorus preserving gastrectomy versus laparoscopic distal gastrectomy

Conditions: Gastric Cancer

Summary: the aim of this study is to show better postoperative quality of life including lower incidence of dumping syndrome and comparable survival after laparoscopic pylorus preserving gastrectomy (lppg), compared to laparoscopic distal gastrectomy (ldg) in patients with middle-third early gastric cancer

participating surgeons prior to this clinical trial, only the surgeons who are considered to have the standardization by review committee participated. patients registration it is required to ensure that the patients meet the inclusion criteria for this clinical trial, are free from any items of exclusion criteria, are explained about the participation in the clinical trial along with the informed consent forms. after rechecking the patients with the registration check list by accessing the web-based randomized program provided from seoul national university hospital medical research collaborating center. each group 128 patients, total 256 subjects will be enrolled. randomization the registration randomization should be done with 1:1 ratio for each researcher. baseline number (bn) should be provided to the subjects in the order of acquisition of informed consent form. based on the subjects who are selected as the appropriate subjects in the end, the allocation number (an) shall be provided in the order of randomized allocation table. procedure operations are performed according to the allocated group.

Eligibility criteria:
inclusion criteria: patients are included in the trial if they meet all of the following criteria: * histologically proven primary gastric adenocarcinoma * aged 20-80 years old * performance status (ps) of 0 or 1 on eastern cooperative oncology group (ecog) scale * performance status (ps) of i to iii on american society of anesthesiologists (asa) score * clinical stage t1n0m0, which are assessed by endoscopic ultrasound or computed tomography (ct) scan (ajcc 7th classification) * location of primary tumor; middle third of stomach (more than 5cm away from the pylorus) * written signed informed consent exclusion criteria: patients are excluded if they meet any of the following criteria: * pyloric deformity because peptic ulcer disease * previous gastric surgery (e.g. gastro-jejunostomy, primary closure) * synchronous lesion of early gastric cancer or adenoma in antrum * prior treatment of endoscopic submucosal dissection, chemotherapy or radiation therapy against any other malignancies * patients who need combined resection (eg. cholecystectomy) * vulnerable patients (lack of decision-making capacity, pregnant, or breast-feeding women) * participated in another clinical trial within the last six months or currently involved patients
personalized dietary intervention based on microbiome analysis vs fodmap diet for irritable bowel syndrome

Conditions: Irritable Bowel Syndrome; Irritable Bowel Syndrome With Diarrhea; Irritable Bowel Syndrome With Constipation; Irritable Bowel Syndrome Mixed

Summary: irritable bowel syndrome (ibs) is a well-known risk factor for diseases of the anal region (hemorrhoids, anal fissures, etc.) and large intestine (colon cancer, diverticular disease). untreatable ibs disease not only impairs the patient's quality of life but also reduces the success of surgical treatment in these diseases. today, only one-third of ibs patients achieve successful results with the treatment methods and diets used routinely. balancing the composition of the gut microbiota may yield satisfactory results in this patient group. with the results of our study, we aim to reveal the effect of microbiome analysis and personalized diet on symptoms and its place in treatment in patients with ibs disease. patients applying to gastroenterology outpatient clinics in respective centers due to ibs will be randomized into two groups. the patients in the control group will follow the fodmap diet protocol for ibs; in the study group, a personalized diet will be applied according to the gut microbiota. no nutritional supplements will be used in either group. changes in defecation habits and quality of life scale of both groups will be evaluated at the end of 6 weeks and the results will be compared.


Eligibility criteria:
inclusion criteria: * to be between the ages of 18-65 * to be diagnosed with ibs (ibs-d, ibs-c, ibs-m) according to the rome iv criteria * to give consent to participate in the study voluntarily * being a smartphone and/or internet user (for dietitian follow-up and clinical follow-up) * not meeting any of the exclusion criteria exclusion criteria: * pregnant or planning to become pregnant * having another known diagnosis of gastrointestinal disease (inflammatory bowel disease, malabsorption of any macronutrient, intestinal resection, celiac disease, etc.) * colonoscopy history (in the last 1 year) * history of abdominal surgery other than appendectomy or hysterectomy * psychiatric comorbidity * chronic diseases that will affect the microbiome (cancer, diabetes, cardiovascular disease, liver diseases, neurological diseases, etc.) * use of drugs that may affect digestive function in the 4 weeks prior to the study (antibiotics (including use in the last 4 weeks), probiotics, narcotic analgesics, lactulose (prebiotics)) * patients taking dietary supplements * excluded from the study if following a restricted diet.

Keywords: microbiome microbiota personalised medicine artificial intelligence
miniject (mini so627) in patients with open angle glaucoma using single operator delivery tool

Conditions: Glaucoma, Open-Angle Glaucoma Eye

Summary: the study will assess safety and performance in patients with open-angle glaucoma uncontrolled by topical hypotensive medications who had previously been implanted with a miniject glaucoma implant.

the study will evaluate the efficacy and safety of mini so627 and iop (intra- ocular pressure) lowering effects with or without the use of glaucoma medications. the procedure will be a stand alone surgery. patient follow up with several examinations up to 24 months after surgery. the primary endpoint is the reduction in medicated mean diurnal iop at 6 months follow up compared to medicated diurnal iop at baseline visit.

Eligibility criteria:
inclusion criteria: * diagnosis of primary or secondary open angle glaucoma during screening/baseline visit or earlier. * grade 3 or grade 4 according to shaffer angle grading system. * glaucoma not adequately controlled by one to four different topical hypotensive medication(s), given each for at least one month, as confirmed by 21mmhg \< iop \< 35 mmhg in the study eye at baseline visit. exclusion criteria: * grade 2 (narrow, 20 degrees), grade 1 (extremely narrow, less or equal to 10 degrees) and grade 0 (closed or slit) according to shaffer angle grading system in the study eye. * neovascular glaucoma in the study eye. * corneal opacity or iridocorneal angle not visible through gonioprism in the study eye, preventing correct placement of the implant in the stud eye. * prior glaucoma surgery in the study eye.

Keywords: glaucoma medical device migs drainage device eye reduction iop
urdu version of cumberland ankle instability tool: reliability and validity study

Conditions: Ankle Sprains

Summary: the purpose of this study is to check reliability and validity, of translated urdu version of the cumberland ankle instability tool develop and test its psychometric properties and responsiveness in urdu speaking population in pakistan endure with ankle sprain and ankle instability complaints.

the urdu version of the cumberland ankle instability tool will be translated and dignified for internal reliability test-retest consistency and cross cultural guidelines of self-reported measures, to evaluate validity (convergent and discrimination)of the sample of 125 participants who experience ankle sprain, participants choose by convenience sampling technique reinforced on already elaborated inclusion/exclusion criteria.evaluation form will be filled by a patient twice an day by observer for inter observer assessment , with an interval of 30 minutes to 2 hours between the first and second application. third assessment will be carried out after 7 days obtained by 1st observer (re-testing),they completed cumberland ankle instability tool urdu version who had ankle sprain in past 3 months and also its correlation checked with lower extremity functional scale, visual analogue scale, and short form - 36 short form health survey participant also completed these scales, in general population with ankle sprain and ankle instability in this study we intended to translate the original version of cumberland ankle instability tool into urdu cross- culturally adaptation and examine psychometric properties and cut-off score of the cumberland ankle instability tool urdu version.

Eligibility criteria:
inclusion criteria: * participants who are 18 years of age and * participants who were able to understand and complete the self-reported questionnaires (native urdu speakers, with at least 8 years of education). exclusion criteria: * people who have ankle sprain episode and/or lower extremity injury within the last 2 months and/or any neurological or neuromuscular disease. * participants were also excluded if they did not fill out 2 or more questions of the urdu version of cumberland ankle instability tool

Keywords: cumberland ankle instability tool urdu version reliability validity ankle sprains ankle instability